Satellos Bioscience has applied to Health Canada for approval of Canadian clinical trials for oral medication SAT-3247, a treatment aimed at rebuilding lost muscle in Duchenne muscular dystrophy, independent of dystrophin levels and mutation. The company also continues to advance their clinical trial programs in the United Kingdom, Europe, Serbia, Australia, and the United States. Satellos expects to enroll the first patient into the Phase 2 study by the end of calendar 2025.

With these moves, the company emphasizes that “our focus is firmly on clinical trial execution for these patients.”

Satellos also recently announced an article in Nature Communications that supports the science of SAT-3247. The research team led by Dr. Michael Rudinicki, co-founder, found that Duchenne is a muscle stem cell condition, and a protein called AAK1 is responsible for preventing stem cells from developing properly. The SAT-3247 treatment approach is to inhibit AAK1 and restore muscle regeneration in Duchenne, independent of dystrophin mutation.

Frank Gleeson, Satellos CEO and co-founder, concludes that “correcting stem-cell dysfunction is essential to changing the trajectory of Duchenne.”

The Phase 1 study found SAT-3247 to be safe, and preliminary efficacy results in Duchenne patients also suggested an increase in lung function and hand grip strength. Defeat Duchenne Canada will continue to monitor Satellos’ progress and report back to our community.  

Update written by Defeat Duchenne Canada Research Volunteer Omar Sheikh.